Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma

Journal of Pineal Research

Volumn 21, Issue 4, 1996, Pages 239-242

  Lissoni, P ^a   Brivio, O ^a   Brivio, F ^a   Barni, S ^a   Tancini, G ^a   Crippa, D ^a   Meregalli, S ^a  

^a SAN GERARDO HOSPITAL   (Italy)

Author keywords

Adjuvant therapy; Cancer endocrine therapy; Melanoma; Melatonin; Pineal gland

Indexed keywords

MELATONIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MALE; MELANOMA; MIDDLE AGED; PATHOLOGY; PINEAL BODY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MELATONIN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PINEAL GLAND; RECURRENCE; TREATMENT OUTCOME;

EID: 0030276855     PISSN: 07423098     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-079X.1996.tb00292.x     Document Type: Article

References (14)

1. BARTSCH, H., C. BARTSCH, D. MECKE, T.H. LIPPERt (1994) Serial transplants of DMBA-induced mammary tumors in Fischer rats as a model system for human breast cancer: I. Effect of melatonin and pineal extracts on slow- and fast-growing passages: in vivo and in vitro studies. Adv. Pineal Res. 8:473-478.
2. BLASK, D.E. (1984) The pineal: an oncostatic gland? In: The Pineal Gland, Reiter, R.J., ed., New York, Raven, pp. 253-284.
3. BLASK, D.E., D.B. PELLETIER, S.M. HILL, A. LEMUS-WILSON, D.S. GROSSO, S.T. WILSON, M.F. WISE (1991) Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: potential involvement of antiestrogenic mechanism in vivo. J. Cancer Res. Clin. Oncol. 117:526-532.
4. CASCINELLI, N. (1995) Evaluation of efficacy of adjuvant r-IFN-alpha 2a in melanoma patients with regional node metastases. Proc. Am. Assoc. Clin. Oncol. 14:1296 (abstr.).
5. GONZALES, R., A. SANCHEZ, J.A. FERGUSON, C. BALMER, C. DANIEL, A. COHN, W.A. ROBINSON (1991) Melatonin therapy of advanced human malignant melanoma. Melanoma Res. 1:237-243.
6. KHAYAT, D., C. BOREL, J.M. TOURANI, A. BENHAMMOUDA, E. ANTOINE, O. RIXE, E. VUILLEMIN, P.A. BAZEX, L. THILL, R. FRANKS, G. AUCLERC, C. SOUBRANE, P. BANZET, M. WEIL (1993) Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J. Clin. Oncol. 11:2173-2180.
7. LISSONI, P., S. BARNI, S. CRISPINO, G. TANCINI, F. FRASCHINI (1989) Endocrine and immune effects of melatonin therapy in metastatic cancer patients. Eur. J. Cancer Clin. Oncol. 25:789-795.
8. LISSONI, P., S. BARNI, G. TANCINI, A. ARDIZZOIA, G. RICCI, R. ALDEGHI, F. BRIVIO, E. TISI, F. ROVELLI, R. RESCALDANI, G. QUADRO, G. MAESTRONI (1994) A randomised study with subcutaneous low-dose interleukin-2 alone vs interleukin-2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br. J. Cancer 69:196-199.
9. MAESTRONI, G.J.M., A. CONTI, W. PIERPAOLİ (1988) Pineal melatonin, its fundamental immunpregulatory role in aging and cancer. Ann. N. Y. Acad. Sci. 521:140-148.
10. POEGGELER, B., R.J. REITER, D.X. TAN, L.D. CHEN, L.C. MANCHESTER (1993) Melatonin, hydrohyl radical-mediated oxidative damage, and aging: a hypothesis. J. Pineal Res. 14:151-168.
11. REITER, R.J. (1995) A review of the evidence supporting melatonin's role as an antioxidant. J. Pineal Res. 18:1-11.
12. REGELSON, W., W. PIERPAOLİ (1987) Melatonin: a rediscovered antitumor hormone? Its relation to surface receptors, sex, steroid metabolism, immunologic response and chronobiological factors in tumor growth and therapy. Cancer Invest. 5:379-385.
13. TARTOUR, E., T. DORVAL, V. MOSSERI, L. DENEUX, C. MATHIOT, H. BRAILLY, F. MONTERO, I. JOYEUX, P. POUILLART, W.H. FRIDMAN (1994) Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br. J. Cancer 69:911-913.
14. YING, S.W., L.P. NILES, C. CROCKER (1993) Human malignant melanoma cells express high-affinity receptors for melatonin: Antiproliferative effects of melatonin and 6-chloromelatonin. Eur. J. Pharmacol. 246:89-96.